Of monkeys and men

Citation for published version:

Digital Object Identifier (DOI):
10.3389/fimmu.2015.00213

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
Frontiers in Immunology

Publisher Rights Statement:
Copyright©2015Pearson,Becker,Driguez,Young,Gaze,Mendes,Li,Doolan, Midzi,Mduluza,McManus,Wilson,Bethony,Nausch,Mutapi,FelgnerandLoukas. Thisisanopen-accessarticledistributedunderthetermsofthe CreativeCommons AttributionLicense(CCBY). Theuse,distributionorreproductioninotherforumsis permitted,providedtheoriginalauthor(s)orlicensorarecreditedandthattheoriginal publicationinthisjournaliscited,inaccordancewithacceptedacademicpractice.Nouse,distributionorreproductionispermittedwhichdoesnotcomplywiththeseterms

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Of monkeys and men: immunomic profiling of sera from humans and non-human primates resistant to schistosomiasis reveals novel potential vaccine candidates

Mark S. Pearson 1, Luke Becker 1, Patrick Driguez 2, Neil D. Young 3, Soraya Gaze 4, Tiago Mendes 5, Xiao-Hong Li 5, Denise L. Doolan 2, Nicholas Midzi 7, Takafira Mduluza 8, Donald P. McManus 2, R. Alan Wilson 9, Jeffrey M. Bethony 10, Norman Nausch 11, Francisca Mutapi 11, Philip L. Felgner 12 and Alex Loukas 1*

1 Centre for Biodiscovery and Molecular Development of Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD, Australia; 2 QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; 3 University of Melbourne, Melbourne, VIC, Australia; 4 Centro de Pesquisas Rene Rachou, Oswaldo Cruz Foundation, Belo Horizonte, Brazil; 5 Federal University of Minas Gerais, Belo Horizonte, Brazil; 6 National Institute of Parasitic Diseases, Shanghai, China; 7 National Institutes of Health Research, Harare, Zimbabwe; 8 Department of Biochemistry, University of Zimbabwe, Harare, Zimbabwe; 9 Department of Biology, University of York, York, UK; 10 Department of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, DC, USA; 11 University of Edinburgh, Edinburgh, UK; 12 University of California Irvine, Irvine, CA, USA

Schistosoma haematobium affects more than 100 million people throughout Africa and is the causative agent of urogenital schistosomiasis. The parasite is strongly associated with urothelial cancer in infected individuals and as such is designated a group I carcinogen by the International Agency for Research on Cancer. Using a protein microarray containing schistosome proteins, we sought to identify antigens that were the targets of protective IgG1 immune responses in S. haematobium-exposed individuals that acquire drug-induced resistance (DIR) to schistosomiasis after praziquantel treatment. Numerous antigens with known vaccine potential were identified, including calpain (Smp80), tetraspanins, glutathione-S-transferases, and glucose transporters (SGTP1), as well as previously uncharacterized proteins. Reactive IgG1 responses were not elevated in exposed individuals who did not acquire DIR. To complement our human subjects study, we screened for antigen targets of rhesus macaques rendered resistant to S. japonicum by experimental infection followed by self-cure, and discovered a number of new and known vaccine targets, including major targets recognized by our human subjects. This study has further validated the immunomics-based approach to schistosomiasis vaccine antigen discovery and identified numerous novel potential vaccine antigens.

Keywords: schistosomiasis, protein microarray, vaccine, human, drug-induced resistance

Introduction

The carcinogenic blood fluke, Schistosoma haematobium, infects more than 100 million people throughout Africa and is the most prevalent of the human schistosomes, causing more than half
of all infections (1). *S. haematobium* adult flukes migrate to the vasculature of the organs of the pelvis. Severe morbidity results from host immune responses to eggs in tissues and includes peri-portal fibrosis, portal hypertension, and hepato-splenic disease (2). Formerly known as urinary schistosomiasis, *S. haematobium* infection was recently renamed “urogenital schistosomiasis” in recognition that the disease affects both the urinary and genital tracts of women and men. Female *S. haematobium* lay between 20 and 200 eggs daily (3), which penetrate the vessel wall and move toward the lumen of the bladder. Some of the eggs become sequestered in the tissue of the pelvic organs such as the urinary bladder, ureters, cervix, vagina, prostate gland, and seminal vesicles, where they cause chronic inflammation, pelvic pain, bleeding, and an altered cervical epithelium in women (4). *S. haematobium* is unique among the schistosomes in its recognition as a group I carcinogen by the International Agency for Research on Cancer because of its robust association with urothelial carcinoma (5). *S. haematobium* infection also increases susceptibility to infection with HIV-1, progression to disease, and results in a higher likelihood of transmitting infection to others (6).

Praziquantel (PZQ) is widely used to treat human schistosome infections and has two main effects on schistosomes – paralysis and tegument damage (7). An added benefit of PZQ treatment is that it mediates destruction of flukes thereby exposing antigens on the worm surface to the host immune system. This release of surface antigens induces and/or enhances parasite-specific immune responses (8), resulting in immune-mediated killing of the parasite. Early studies reported modifications in T-cell proliferative responses (9), whereas recent studies noted modifications in the levels and types of antibody (10–13) and cytokine responses (14–16) following PZQ treatment. The immune response triggered by PZQ treatment is thought to last for more than 1 year (14, 17–19) and confer at least some level of resistance to re-infection. This phenomenon is referred to as “drug-induced resistance” (DIR) (20). The mechanisms behind DIR differ significantly from those of putative natural resistance (PR, resistant individuals who have not received PZQ therapy) and can be related to the origin (developmental stage) and concentration of the released antigen, as well as the type of antigen-presenting cells (APCs) involved. PZQ treatment introduces a large amount of adult fluke antigen directly into the bloodstream as a result of many worms dying at once (21), whereas naturally acquired resistance in the absence of PZQ treatment (PR) is stimulated by the introduction of smaller quantities of adult antigen due to a more gradual worm death. The process of PR is additionally stimulated by the release of antigens from naturally dying larval schistosomes (schistosomula) primarily through the skin and pulmonary vasculature, thus inducing different APCs and resulting in different interactions between the antigens and the immune system (22). This additional stimulus does not appear to factor significantly in DIR due to the inefficacy of PZQ against schistosomula (7, 8). Whatever the mechanism, it is important that an antigen threshold is reached in order to sufficiently stimulate anti-schistosome immunity (23, 24).

Studies with car washers in schistosome-infected waters of Lake Victoria in Kenya showed that a subset of the men developed resistance to re-infection after PZQ therapy while others remained susceptible despite treatment (25, 26). It was found that IgE production to soluble worm antigen preparation (SWAP) paralleled the development of resistance, and did not occur in those who remained susceptible to re-infection (25). Additionally, our own immuno-proteomic studies have used *S. haematobium* SWAP to identify a number of antigens that are released by PZQ treatment and/or are the target of DIR immune responses (27, 28). However, despite the power of these proteomic studies in identifying individual parasite proteins, the utilization of SWAP (where worms are homogenized and solubilized under native conditions in the absence of detergents that will solubilize the cell membranes) does not result in full representation of the *S. haematobium* proteome. Indeed, numerous abundantly expressed proteins with multiple membrane spanning domains that are released from the tegument with detergents (29, 30) are accessible to chemical labeling on the surface of live worms (30), are recognized by sera from PR individuals, and are lead vaccine antigens against schistosomiasis (31–33).

A third mechanism of resistance to schistosomiasis is seen in the rhesus macaque (*Macaca mulatta*). It is unique among animal models of schistosomiasis in that, once an infection reaches patency, worm death starts to occur from week 10 (34) and egg output diminishes over time until the infection is eliminated (35, 36). This phenomenon only occurs above a threshold worm burden (35, 36), presumably as sufficient immune stimulus is required for this process to occur (23, 24). This self-cure mechanism is thought to be antibody-mediated because of a strong inverse association between the rapidity and intensity of the IgG response and the number and morphology of surviving worms (34). Two-dimensional immunoblotting of worm extracts showed the immune response to be directed at gut digestive enzymes, tegument surface hydrolases, and anti-oxidant enzymes (34).

The use of protein microarrays to profile the immune response to pathogens has become widespread over recent years and offers significant advantages over the conventional immuno-proteomic approaches described above. In parasitology, protein array studies have been used extensively in malaria (37) to compare antibodies from un-protected and protected subjects, identifying the antibodies (and their cognate antigens) that confer immunity (38–40). For schistosomes (37), similar studies have profiled antibody responses in *S. japonicum* and *S. mansoni*-infected rodents (41, 42) and human subjects who are naturally resistant or susceptible to *S. mansoni* (20).

Based on the success of our previous immunomics approach which analyzed antibody signatures of PR and chronically infected (CI) individuals from an *S. mansoni*-endemic area of Brazil (20), we decided to use the same experimental approach to identify antigens which are the targets of humoral immune responses in (1) DIR human subjects from an *S. haematobium*-endemic area in Africa and (2) rhesus macaques that had undergone self-cure after experimental *S. japonicum* infection. Given the extensive similarities in protein-coding gene sequences between the three major human schistosomes (86–92%) (41), as well as the extensive recognition of *S. japonicum* proteins on our array by sera from *S. mansoni*-infected individuals (20), we reasoned that sera from *S. haematobium*-infected individuals would strongly recognize many of the arrayed *S. mansoni* and *S. japonicum* proteins. Moreover, these cross-reactive antigens would potentially form
the basis of a pan-schistosome vaccine that protects against all three human species. Leveraging existing protein arrays from our previous study, which contain antigens primarily from the antibody-accessible teguments of the adult fluke and the immunologically vulnerable schistosomulum stage, we show that DIR individuals and self-curing rhesus macaques make robust antibody responses to a number of tegument-associated proteins, including novel and previously described schistosome vaccine candidates.

Materials and Methods

Ethical Statement

Ethical and institutional approval was granted by the Medical Research Council of Zimbabwe and the University of Zimbabwe Institutional Review Board. Local permission for the study was granted by the Provincial Medical Director. The study design, aims, and procedures were explained in the local language, Shona, prior to enrollment. Participants were free to drop out of the study at any time and informed written consent was obtained from all participants prior to taking part in the study and to receiving anthelmintic treatment. As routine, all participants were offered treatment with the standard dose of PZQ (40 mg/kg) at the end of the study. All work involving experimental procedures with Rhesus macaques was approved by the Ethics Committee of Kunming Institute of Zoology, Chinese Academy of Sciences (CAS) (ID: SYDW-2011017).

Study Cohort

The study participants were residents of a *S. haematobium*-endemic rural village in Murewa in the Mashonaland East Province of Zimbabwe (31°9.4′E; 17°67′S). The village was selected because health surveys regularly conducted in the region showed little or no infection with soil-transmitted helminths (STH) and a low *S. mansoni* prevalence (<2%). Serum samples were provided from a cohort of *S. haematobium*-infected individuals (*n* = 106) aged 5–14 years who had never been treated with PZQ prior to this study and were free from co-infection with other helminths, *Plasmodium*, and HIV (1,4,44). At the start of the study (baseline), subjects who were positive for *S. haematobium* eggs (at least one egg found in at least one of three urine samples, each collected on a separate day) following urinalysis were treated with PZQ by weight (40 mg/kg) and then assessed by urinalysis at 6 weeks to confirm clearance of the infection (no eggs found in any of three urine samples, each collected on a separate day). Individuals were followed for 18 months and maintained regular water contact throughout this period. Subjects were assessed for infectivity with *S. haematobium* at 6 months and at the end of the study. Individuals who were egg-positive at 18 months post-treatment (*n* = 32) were deemed CI and those who were egg-negative (*n* = 74) were categorized as DIR (Figure 1). Serum samples were obtained from both 0- and 18-month timepoints.

For this study, we selected a subset of subjects as follows: CI subjects that had the highest post-treatment egg burdens (eggs/10 ml 10–104; *n* = 10) and DIR subjects that had some of the highest egg burdens at baseline (eggs/10 ml 44–743; *n* = 10), reasoning that these individuals represented extremes of the DIR and CI spectrums and therefore would maximize the likelihood of identifying differences in antibody signatures between CIs and DIRs. Subject ages (in years) were as follows: CIs (5, 8, 8, 9, 10, 11, 11, 12, 14), range = 5–14, mean = 9.8, median = 10; DIRs (6, 8, 8, 8, 9, 9, 10, 11, 12), range = 6–12, mean = 8.9, median = 8.5.

Infection of Self-Curing Rhesus Macaques

The study used six captive-bred adult male rhesus macaques (*M. mulatta*; mean age 9.67 ± 0.82 years, mean weight 7.98 ± 0.85 kg) from the Kunming Primate Research Center, CAS. Macaques were group-housed prior to the experiment but then singly after infection for fecal sampling. Cercariae of *S. japonicum* were shed from patent snails (*Oncomelania hupensis*) provided by the Jiangsu Institute of Parasitic Diseases (Wuxi, China), collected from the water surface using a bacteriological loop and placed on glass cover slips for infection. Rhesus macaques anesthetized with ketamine hydrochloride (6 mg/kg body weight, Gutian Pharmaceutical Corporation, Fujian, China) were infected percutaneously with 600 cercariae via the shaved abdominal skin for 30 min. Blood was obtained by intravenous sampling prior to infection (week 0) and at 12 and 20 weeks after exposure. Elimination of infection was confirmed at week 20 by assessment of eggs per gram of feces using both the Percoll technique (45) and Kato-Katz method (46).

Probing of Protein Microarrays with Human and Macaque Sera

Protein microarrays were leveraged from a previous study by us (20) and contained both *S. mansoni* (*n* = 45) and *S. japonicum* (*n* = 172) proteins which were either (1) known or predicted to be localized to the tegument and/or (2) expressed in the schistosomulum (41), which is vulnerable to immune attack. Human IgG1 and IgE responses to antigens were determined by probing arrays with sera as previously described (20). Macaque antibody responses

![Figure 1](image-url)
were determined by probing of arrays with sera as described for human sera with the exception that a goat anti-monkey IgG-biotin (1:500) (Sigma) secondary antibody was used.

**Protein Array Data Analysis and Bioinformatics**

Array data analysis was conducted using the “group average” method (20), where the mean signal intensity (SI) of the negative control (empty vector) spots for all sera were subtracted from the SI of each protein spot. The following reactivity cut-offs (calculated as one standard deviation above the negative control spots for all groups) were used: human IgG1 – 8239; human IgE – 1861; macaque IgG – 3210. Statistical analyses (Student’s t-test) were conducted with Graphpad Prism 6 to determine significant differences between samples for a given reactive protein.

The transcription of genes in the adult and egg stages of *S. haematobium* was assessed for *S. haematobium* orthologs of all arrayed *S. mansoni* and *S. japonicum* proteins that were the targets of significantly different IgG responses between DIR and CI post-treatment sera using publicly available RNA-seq data (43). These data were filtered for quality (PHRED score of >30) using Trimmmomatic (47) and aligned to the open reading frames of the published gene set (43) using Bowtie (v2.1.0) (48). Normalized levels of gene transcription were calculated using the software package RSEM (v1.2.11) (49) and reported as the numbers of transcripts per million reads sequenced (TPMs). The TPM value of each gene was log2-transformed and subjected to heat map visualization using R (v3.1.2)1, and utilizing the heatmap.plus (v1.3)2 package.

**Results**

**Antibody Signatures of DIR Human Subjects Differ Before and After PZQ Treatment**

To investigate the difference in antibody responses to arrayed antigens of the DIR cohort before and after PZQ treatment (therefore identifying antigens which are putatively exposed by drug therapy), sera from this group at baseline and 18 months after drug therapy were used to probe protein microarrays. IgG1 responses were significantly higher in DIRs at 18 months post-treatment compared to baseline for all 24 reactive proteins. Antigens which were the target of the most significantly different (p < 0.0001) responses pre- and post-drug treatment included AY810792 (butylcholinesterase), AY812951 (mastin), and AY815196 (Ig domain-containing, sensory guidance protein) (Figure 2A). In contrast, IgG1 responses of the CI cohort to reactive proteins before and after PZQ treatment were not significantly different for any protein (data not shown). Additionally, IgE responses in the DIR group were significantly lower at 18 months post-PZQ treatment compared to baseline for the majority (78%) of the 18 reactive antigens (Figure 2B). Arranged antigens that were the targets of IgE in post-treatment DIRs included AY810792 (cholinesterase), AY812951 (mastin), and AY815196 [a homolog of human tetraspanin (TSP)-33 (51)] (Figure 3). Homologs and/or family members of known schistosome vaccine candidates such as calpain (50) (AY814430), a 28-kDa GST – Sh2GST (51) (AY815303), and the TSPs Sm-TSP-1 and Sm-TSP-2 (33, 52) (AY815196) were also identified. Table 1 lists all of the antigens depicted in Figure 3 along with their *S. haematobium* orthologs as we reasoned that these were probably the native parasite antigens that our DIR and CI sera were targeting during the course of *S. haematobium* infection. Of the 20 antigens that were targets of significantly elevated IgG1 responses in post-treatment DIRs compared to CIs, only 7 (35%) were targets of IgE responses that were deemed to be above the reactivity cut-off (Figure 4).

![Figure 2](http://www.R-project.org/web/packages/heatmap.plus)

**IgG1 Profiles Differ Between S. haematobium-Infected Humans Who Do and Do Not Acquire DIR After PZQ Treatment**

In order to analyze changes in antibody signatures to arrayed antigens related to the acquisition of DIR (thereby identifying proteins which are potential inducers of a protective antibody response), arrays were interrogated with sera from post-treatment CIs and DIRs and probed for IgG1 reactivity. IgG1 responses were significantly elevated in DIRs compared to CIs at 18 months to 20 of the 24 (83%) reactive proteins. The three antigens that were targets of the most significantly different (p < 0.0001) IgG1 responses were AY810792 (butylcholinesterase), AY812951 (mastin), and AY815196 [a homolog of human tetraspanin (TSP)-33 (51)] (Figure 3). Homologs and/or family members of known schistosome vaccine candidates such as calpain (50) (AY814430), a 28-kDa GST – Sh2GST (51) (AY815303), and the TSPs Sm-TSP-1 and Sm-TSP-2 (33, 52) (AY815196) were also identified. Table 1 lists all of the antigens depicted in Figure 3 along with their *S. haematobium* orthologs as we reasoned that these were probably the native parasite antigens that our DIR and CI sera were targeting during the course of *S. haematobium* infection. Of the 20 antigens that were targets of significantly elevated IgG1 responses in post-treatment DIRs compared to CIs, only 7 (35%) were targets of IgE responses that were deemed to be above the reactivity cut-off (Figure 4).

---

2. http://cran.r-project.org/web/packages/heatmap.plus
Transcription Analysis
The transcription of genes in the adult and egg stages of *S. haematobium* was assessed for orthologs of all 20 arrayed *S. mansoni* and *S. japonicum* proteins that were the target of significantly different DIR IgG responses post-treatment using publicly available RNA-seq data. We did not find any significant difference in the level of transcription between life stages for a given protein. MS3_02176 (the gene encoding microsomal GST-3) was expressed most highly and relatively constitutively in all developmental stages examined (Figure 5).

IgG Profiles of *S. japonicum*-Infected Self-Curing Rhesus Macaques Differ During the Course of Infection
To investigate IgG responses of rhesus macaques to arrayed proteins during the course of a self-curing infection, protein arrays were probed with sera taken at week 0 (primary infection), week 12, and week 20 (after parasite elimination). Antibody responses to all (eight proteins – Table 1) but one reactive protein (AY812195 – extracellular SOD) were significantly elevated between 0 and 12 weeks post-infection (p.i.), with the three most robust and highly significant responses being aimed at proteins of unknown function (AY815838 and AY812161) and a MARVEL domain-containing lipid-raft-associated protein (AY815056). The IgG reactivity of only one protein (AY812195 – extracellular SOD) was elevated at 20 weeks compared to 12 weeks p.i. (Figure 6; Table 1).

Three Different Disease Models of Resistance to Schistosomiasis Reveal Common Reactivity to Some Arrayed Proteins
We searched for reactive proteins common to DIR human subjects, *S. japonicum*-infected self-curing rhesus macaques (both described herein), and humans living in an *S. mansoni*-endemic area of Brazil who, unlike DIRs, have never been treated with PZQ but are putatively resistant to infection (20). Three reactive proteins were common targets of “protective” antibody responses in the DIR and macaque models: a MARVEL domain-containing lipid-raft-associated protein; a glucose transporter (SGT1); and an extracellular SOD (although the IgG response to this protein was not significantly elevated between DIRs and CIs after PZQ treatment). Two reactive antigens were commonly recognized by both DIRs and PRs: ribosome-binding protein 1 and the beta subunit of Na+/K+ ATPase (SNaK1β) (Figure 7).

Discussion
The critical role that antibodies play in resistance to schistosomiasis resistance has been well established in animal models by numerous passive transfer studies [e.g., Ref. (59, 60)], and there is evidence that some mechanisms of protective immunity in humans are antibody-mediated, both in individuals naturally resistant to schistosomiasis (20) and those who acquire resistance after PZQ therapy (25). Herein, we describe the antibody reactivity profiling of a schistosome protein array with sera from *S. haematobium*-exposed DIR and CI individuals and rhesus macaques self-cured of a *S. japonicum* experimental infection (34) in an effort to identify schistosome antigens that might be the targets of resistant human and non-human primate hosts. We previously utilized this protein microarray to define the antibody signatures of individuals that are either naturally resistant to or CI with *S. mansoni* in a schistosome endemic area of Brazil (20). We restricted our antibody isotype analyses to IgG1 and IgE. IgG1 is one of the main drivers of the protective humoral response to schistosomiasis (23, 24), an observation supported by studies showing that key tegument vaccine antigens like Smp80 (calpain), Sm-TSP-2, and Sm29 are the targets of these responses in schistosome-resistant individuals (32, 33, 61). IgE is thought to be critical in resistance to schistosomiasis, including the DIR process (25, 62, 63), but caution is warranted in development of anti-helminth vaccines that drive IgE responses due to potential anaphylactic responses in individuals who are pre-sensitized from chronic helminth infection/exposure (64).

Significantly elevated IgG1 responses were detected to 24 antigens in DIR subjects 18 months after therapy compared to pre-treatment responses. In stark contrast, we did not detect elevated IgG1 responses to any proteins in CI subjects at 18 months post-treatment compared to pre-treatment levels. None of these antigens were recognized in a previous study by us in which pooled sera from *S. haematobium*-exposed individuals before and after PZQ treatment were used to probe 2D gels containing *S. haematobium* SWAP (27), likely because the majority of proteins on the array are membrane-associated tegument proteins and might not be well represented in SWAP due to the very mild solubilizing nature (Tris) of the preparation.

It is noteworthy that IgG1 reactivity to a further 105 (48%) arrayed antigens was significantly higher in post- compared to pre-treatment DIRs but signal intensities were below the cutoff, so the proteins were deemed non-reactive. This decreased level of reactivity possibly reflects the heterogeneity of the antigen–antibody interaction, i.e., antibodies to *S. haematobium* proteins are reacting with a protein array containing *S. mansoni* and *S. japonicum* antigens. Indeed, significant differences in...
### TABLE 1 | Arrayed proteins significantly reactive to *S. haematobium*-infected DIR post-treatment sera and *S. japonicum*-infected, self-curing rhesus macaque sera.

<table>
<thead>
<tr>
<th>Array ID (GenBank accession number)</th>
<th>Description</th>
<th>Reactivity difference* (p value)</th>
<th>Frequency of recognition (%)</th>
<th>S. haematobium homolog; amino acid identity with arrayed antigen</th>
<th>Therapeutic use</th>
</tr>
</thead>
<tbody>
<tr>
<td>AY810792</td>
<td>Butylcholinesterase (<em>S. japonicum</em>)</td>
<td>$6.97 \times 10^{-6}$</td>
<td>100</td>
<td>Acetylcholinesterase; 86%</td>
<td>IgG to <em>S. mansoni</em> AchE drives complement-mediated killing of somules by 75–95% (53)</td>
</tr>
<tr>
<td>AY812951</td>
<td>Mastin (<em>S. japonicum</em>)</td>
<td>$7.10 \times 10^{-6}$</td>
<td>90</td>
<td>Plasminogen; 70%</td>
<td>Vaccination with members of this family (<em>Sm</em>-TSP-1 and <em>Sm</em>-TSP-2) induces 65–69% protection in a mouse model of schistosomiasis (53); Vaccination with a member of this family (<em>Sj</em>23) induces 35% protection in a mouse model of schistosomiasis (54)</td>
</tr>
<tr>
<td>AY815196</td>
<td>Similar to NM_079585 tetraspanin 86D in <em>Drosophila melanogaster</em> (<em>S. japonicum</em>)</td>
<td>$1.40 \times 10^{-5}$</td>
<td>50</td>
<td>Tetraspanin-33; 81%</td>
<td></td>
</tr>
<tr>
<td>AY815945</td>
<td>SJCHGC09124 protein (<em>S. japonicum</em>)</td>
<td>$2.29 \times 10^{-5}$</td>
<td>100</td>
<td>Hypothetical protein; 73%</td>
<td></td>
</tr>
<tr>
<td>AY809911</td>
<td>SJCHGC02149 protein (<em>S. japonicum</em>); putative immunoglobulin domain superfamily (sensory guidance protein) (<em>S. mansoni</em>); 90% homology</td>
<td>$3.06 \times 10^{-5}$</td>
<td>100</td>
<td>Hypothetical protein; 87%</td>
<td></td>
</tr>
<tr>
<td>C609117.1</td>
<td>Succinate dehydrogenase (<em>S. mansoni</em>)</td>
<td>$1.37 \times 10^{-4}$</td>
<td>100</td>
<td>Succinate dehydrogenase cytochrome b560 subunit, mitochondrial; 93%</td>
<td></td>
</tr>
<tr>
<td>AY815690</td>
<td>Myosin-7 (<em>S. japonicum</em>)²</td>
<td>$2.25 \times 10^{-4}$</td>
<td>80</td>
<td>Ribosome-binding protein 1; 90%</td>
<td></td>
</tr>
<tr>
<td>AY812591</td>
<td>SJCHGC04069 protein (<em>S. japonicum</em>)</td>
<td>$4.25 \times 10^{-4}$</td>
<td>100</td>
<td>Hypothetical protein (RNA binding); 71%</td>
<td></td>
</tr>
<tr>
<td>AY222868</td>
<td>SJCHGC06654 protein (<em>S. japonicum</em>)</td>
<td>$4.45 \times 10^{-4}$</td>
<td>90</td>
<td>Large subunit ribosomal protein; 48%</td>
<td></td>
</tr>
<tr>
<td>AY808953</td>
<td>Zinc finger CCCH domain-containing protein 3 (<em>S. japonicum</em>)</td>
<td>0.0023</td>
<td>100</td>
<td>Hypothetical protein; 41%</td>
<td></td>
</tr>
<tr>
<td>AY814497</td>
<td>SJCHGC02432 protein (<em>S. japonicum</em>)</td>
<td>0.0027</td>
<td>100</td>
<td>Hypothetical protein; 58%</td>
<td></td>
</tr>
<tr>
<td>AY814261</td>
<td>Ectonucleotide pyrophosphatase/phosphodiesterase family member 5 (<em>S. japonicum</em>)</td>
<td>0.0033</td>
<td>90</td>
<td>Ectonucleotide pyrophosphatase/phosphodiesterase family member 5; 67%</td>
<td></td>
</tr>
<tr>
<td>AY816000</td>
<td>Cytochrome b-561 (<em>S. japonicum</em>)</td>
<td>0.0081</td>
<td>60</td>
<td>Cytochrome b-561; 85%</td>
<td></td>
</tr>
<tr>
<td>AY815303</td>
<td>Similar to microsomal glutathione S-transferase in <em>Oryctolagus cuniculus</em> (<em>S. japonicum</em>)</td>
<td>0.0099</td>
<td>50</td>
<td>Microsomal glutathione S-transferase 3; 85%</td>
<td></td>
</tr>
</tbody>
</table>

*Note:
1. GenBank accession number
2. Description/aa homology
3. Length (aa) and TM domains

(Continued)
### Table 1 | Continued

<table>
<thead>
<tr>
<th>Array ID</th>
<th>Description</th>
<th>Reactivity difference(^a)</th>
<th>Frequency of recognition (%)</th>
<th>S. haematobium homolog; amino acid identity with arrayed antigen</th>
<th>Therapeutic use</th>
</tr>
</thead>
<tbody>
<tr>
<td>AY810700</td>
<td>Solute carrier family 2 protein (S. japonicum)</td>
<td>0.0100</td>
<td>50</td>
<td>MS3_02545</td>
<td>Solute carrier family 2, facilitated glucose transporter member 1; 85%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Suppression of S. mansoni ortholog (SGTP1) impairs the parasite's ability to establish infection in vivo (56)</td>
</tr>
<tr>
<td>AY812972</td>
<td>SJCHGC02374 protein (S. japonicum)</td>
<td>0.0106</td>
<td>60</td>
<td>MS3_11481</td>
<td>Hypothetical protein; 90%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AY814817</td>
<td>SJCHGC06849 protein (S. japonicum)</td>
<td>0.0130</td>
<td>90</td>
<td>MS3_05945</td>
<td>Hypothetical protein (TATA-box binding); 71%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AY812195</td>
<td>Extracellular superoxide dismutase (Cu–Zn) (S. japonicum)</td>
<td>0.0071(^f)</td>
<td>83</td>
<td>N/A</td>
<td>S. mansoni ortholog (SmCT-SOD) induces 59% protection in a mouse model of schistosomiasis (58)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AY810700</td>
<td>Solute carrier family 2 protein (S. japonicum)</td>
<td>0.0100</td>
<td>50</td>
<td>MS3_02545</td>
<td>Solute carrier family 2, facilitated glucose transporter member 1; 85%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Suppression of S. mansoni ortholog (SGTP1) impairs the parasite's ability to establish infection in vivo (56)</td>
</tr>
<tr>
<td>AY812195</td>
<td>Extracellular superoxide dismutase (Cu–Zn) (S. japonicum)</td>
<td>0.0071(^f)</td>
<td>83</td>
<td>N/A</td>
<td>S. mansoni ortholog (SmCT-SOD) induces 59% protection in a mouse model of schistosomiasis (58)</td>
</tr>
<tr>
<td>AY810700</td>
<td>Solute carrier family 2 protein (S. japonicum)</td>
<td>0.0100</td>
<td>50</td>
<td>MS3_02545</td>
<td>Solute carrier family 2, facilitated glucose transporter member 1; 85%</td>
</tr>
<tr>
<td>AY812195</td>
<td>Extracellular superoxide dismutase (Cu–Zn) (S. japonicum)</td>
<td>0.0071(^f)</td>
<td>83</td>
<td>N/A</td>
<td>S. mansoni ortholog (SmCT-SOD) induces 59% protection in a mouse model of schistosomiasis (58)</td>
</tr>
</tbody>
</table>

\(^a\)For DIR-reactive proteins, difference is in elevation of IgG1 response of DIRs compared to CIs post-treatment.

\(^b\)Transmembrane (TM) domains predicted by TMHMM 2.0. For full-length proteins, first TM domain contains an N-terminal signal sequence.

\(^c\)Proteins lack start methionine.

\(^d\)We believe the sequence represented by AY815690 ["myosin-7 (S. japonicum)"] has been incorrectly annotated due to its high degree of homology with other parasite orthologs of ribosome-binding protein 1 and lack of hits with any form of myosin.

\(^e\)Difference in elevation of IgG response between 0 and 12 weeks p.i.

\(^f\)Difference in elevation of IgG response between 0 and 20 weeks p.i.
antibody recognition patterns were observed when using sera from *S. haematobium*-exposed people to probe crude antigen preparations from the closely related *S. bovis*, and vice versa (65). Moreover, sequence variation in the epitopes of *Sh*28GST, and its homologs from *S. mansoni* and *S. bovis* significantly altered the immune response generated by the host (66). Twenty reactive arrayed antigens were the targets of significantly greater IgG1 responses in DIRs compared to CIs post-treatment. A further 72 (33%) proteins were the target of significantly different IgG1 recognition profiles between DIRs and CIs but were below the reactivity cut-off. We hypothesize that at least some of these IgG1-reactive proteins are major targets of protective immunity, engendering resistance to schistosomiasis through an antibody-mediated neutralization of the cognate antigen, the role of which is essential to the survival of the parasite within the host (e.g., nutrient acquisition, immune evasion) such that disruption of its function results in worm impairment. Indeed, some of these antigens are protective in animal challenge models of schistosomiasis; for example, vaccination with and the Ca<sup>2+</sup>-activated protease, calpain (*AY814430*), induces 64% in baboons (50). *Sh*28GST (a homolog of the arrayed immunoreactive protein *AY813303*) is a multi-functional enzyme present in the tegument and sub-tegument of adult (67) and larval (68) schistosomes and the current focus of vaccine trials in humans (51). Its exact function is unknown [studies suggest it may aid in immune evasion by the parasite through its role in fatty acid metabolism and prostaglandin D<sub>2</sub> synthesis (69), but vaccine efficacy has been attributed to the induction of antibodies that neutralize enzyme activity (70)]. Other extracellular enzymes were prominent amongst the IgG1-reactive proteins, including proteases (calpain, mastin), esterases, and superoxide dismutase, so it is tempting to speculate that antibodies to these enzymes neutralize key physiological processes (71, 72), and this now warrants further investigation. Members of the TSP family in schistosomes (*Sm*-TSP-1 and *Sm*-TSP-2) are four-transmembrane domain proteins located within the tegument of larval and adult worms that have functions in membrane biogenesis (73). TSP-based vaccines have shown to be efficacious against schistosomiasis with *Sm*-TSP-1 and *Sm*-TSP-2 (33, 52) and *Sj*23 (54, 74) conferring protection in animal challenge models.

Other significant IgG1 responses were aimed at tegument-associated proteins that play fundamental roles in parasitism. Surface-associated acetylcholinesterase (AChE) (*AY810792*) has been implicated in the regulation of glucose scavenging from host blood (75) and anti-AChE antibodies facilitate complement-mediated killing of larval schistosomes (53). Genes encoding the glucose transporter SGTPI (*AY810700*), Na<sup>+</sup>/K<sup>+</sup> ATPase subunit SNaK1β (*AY814977*) and ectonucleotide pyrophosphatase/phosphodiesterase SmNPP-5 (*AY814261*) have all been functionally silenced within schistosomes using RNAi (55–57), resulting in impairment of the worm’s ability to establish infection in the host and highlighting their importance to parasite survival.

Significantly IgG1-reactive proteins whose therapeutic potential has not yet been examined include mastin (*AY812951*) and a MARVEL domain-containing lipid-raft-associated protein (*AY815056*). Mastin is a trypsin-like serine protease and, in schistosomes, proteases of this class are known as cercarial elastases (CEs) for their role in skin degradation to facilitate penetration of the free-living cercaria into the definitive host (76). Mastin, however, differs in structural homology to CEs and has been assigned to a group of “non-CE” serine proteases (77). The five members of this group are yet to be functionally characterized in terms of their roles in parasitism, but mastin is unique in that it is highly upregulated in the intra-mammalian schistosome adult stages (60 and 150% relative to the constitutively expressed *smcox1*, respectively (77) compared to the free-living stages of the parasite (78, 79), alluding to a fundamental parasitic function]. MARVEL domains have four-transmembrane helix architecture and proteins containing these motifs associate with membrane micro-domains and have been implicated in membrane biogenesis (80). In a pathogenesis context, the MARVEL domain-containing protein Nce102 regulates actin organization and invasive growth of *Candida albicans*, with Nce102 deletion mutants showing decreased virulence in mice (81). Antigens such as mastin and the MARVEL domain protein are attractive vaccine candidates for the reasons described herein as well as the successful use of proteases (82–84) and membrane structural proteins as anti-helminth vaccines [e.g., Ref. (33, 54, 85, 86)].

A group of ribosome-associated proteins were also the targets of significantly higher IgG1 responses in DIRs compared to CIs post-treatment and included ribosome-binding protein 1. Ribosome-associated proteins have received attention in the field of parasite immunology because of their classification as “patho-antigens” – conserved intracellular molecules capable of inducing an immunopathological response (87). Patho-antigens such as acidic ribosomal protein P0 conferred protection as vaccines against the intracellular parasites *Leishmania major* (87) and *Plasmodium yoelii* (88) in mouse challenge models of infection, and antibodies to *P. falciparum* P0 have been detected in individuals who are immune to malaria (89). The roles of these antigens, such as ribosome-binding protein 1, in the induction of anti-schistosome immunity is unclear, but it is possible that these intracellular molecules are stimulating host immune effectors through exosome-mediated pathways [recently identified in related helminths (90, 91)]. It should also be noted that
riboosome-binding protein 1 was one of the two antigens recognized by both S. mansoni-exposed PR subjects in Brazil and S. haematobium-exposed DIR subjects in Africa (Figure 6), possibly highlighting a common role in different mechanisms of schistosomiasis resistance.

IgE responses to arrayed antigens were, for the most part, significantly weaker in post-therapy DIRs compared to pre-treatment responses, which appears to be in contrast to the positive association between IgE levels and the process of acquiring DIR status (25, 62). This could be likely for two reasons: (1) these earlier studies on DIR employed soluble antigen preparations to detect IgE responses, whereas the majority of arrayed proteins are membrane-associated and therefore would not have been present in buffer-soluble parasite extracts or (2) the DIR cohort, being egg-negative, does not receive the IgE-inducing stimulus of egg antigens (92). The latter explanation may be supported by the case of extracellular SOD (AY812195); the IgE response to this protein was significantly lower in egg-negative, post-treatment DIRs (Figure 2B) but significantly higher in egg-positive, post-treatment CIs (data not shown). Indeed, a recent study describing the prediction of IgE-binding antigens in S. mansoni-infected individuals reported no significant change in the IgE response to extracellular SOD before and 5 weeks after PZQ treatment (93), which lends support to the observation that the waning IgE response to some antigens in DIRs might be due to the reduced amount of IgE-inducing stimulus received by this cohort. Less than half of the antigens that were significantly reactive for DIR post-treatment IgG1 compared to pre-treatment levels were reactive (above the cut-off) for IgE responses.

IgE poses somewhat of a conundrum for helminth vaccinologists due to its clear association with naturally acquired protection (22, 63), but the accompanying risk of vaccinating people with a recombinant protein that is the target of pre-existing IgE responses and poses the risk of inducing atopy (64), or potentially...
anaphylaxis. Instead of excluding potentially protective IgG1-inducing antigens that are the targets of parasite-derived IgE in exposed individuals from further vaccine development, we propose that the molecules be assessed for allergenicity through the use of basophil-activation studies, given that the induction of IgE and clinical manifestation of allergy are not mutually inclusive events (94). Another strategy aimed at minimizing potential allergenicity of helminth proteins involves their fusion to Fcγ, thereby directing the chimeric protein to the negative signaling receptor FcγRIIB expressed on pro-allergic cells (95).

The IgG1 response in *S. japonicum*-infected self-curing macaques to the majority of reactive antigens was significantly higher at 12 weeks p.i. [around the time that worm death starts to occur (34)] compared to week 0. Proteins that were the target of these antibodies included a protein with weak sequence homology to a bacterial hydrodase (AY815838), extracellular SOD (AY812195), and the previously discussed glucose transport and MARVEL domain-containing proteins. Extracellular SOD is thought to facilitate the parasite’s evasion of the immune response by neutralizing the effects of reactive oxygen and nitrogen species and has proven efficacious in murine vaccine trials (58). Moreover, both hydrolases and anti-oxidant enzymes were suggested to be the targets of IgG-mediated worm elimination in a previously established macaque self-cure model of schistosomiasis (34).

Given the cognate recognition of antigen by both B and helper T cells in the immune response, we hypothesize that the best antigens for a recombinant protein vaccine are those that elicit responses by both antibodies and T cells during the acquisition of DIR. The antigens described herein should now be subjected to further refinement by assessing their ability to drive T-cell proliferation *ex vivo*. T-cell profiling of B-cell antigens has been conducted for the vaccinia virus (discovered using protein array profiling) where plasmids encoding arrayed proteins were expressed as inclusion bodies and screened for T-cell reactivity in a high-throughput format (96).

In this pilot study, we have described the screening of a schistosome protein array to identify potential targets of protective immunity in *S. haematobium*-infected people who acquire DIR after PZQ treatment, with the hypothesis that these antigens are responsible for essential parasitic functions such that antibody-mediated neutralization of these molecules result in worm impairment or death. While the modest number of targets identified from this work may be reflective of the heterogeneity between the antigens and sera used in the study, a benefit of this approach is the identification of proteins that are cross-reactive between *S. haematobium*, *S. japonicum*, and *S. mansoni*, a desirable feature of a vaccine antigen if it is to be protective against all medically important schistosome species. If a pan-schistosome vaccine is developed, it will likely be part of a control program that integrates a vaccination cocktail of multiple recombinant antigens with chemotherapy, and so a comprehensive portfolio of the targets of DIR is a crucial component of the vaccine discovery strategy. Future iterations of our protein array will be expanded to represent even more of the schistosome proteome, ensuring that an extensive complement of DIR-reactive vaccine antigens will be available for progression into further development.

**Acknowledgments**

We would like to thank the residents and children of Chipinda village as well as the teachers from Chipinda primary and secondary school for their participation and generous and kind support.
of this study. We are also very grateful for the co-operation of the Ministry of Health and Child Welfare in Zimbabwe. We like to thank the Provincial Medical Director of Mashonaland East, the Environmental Health Workers, and nursing staff at Chitake Clinics and Murehwa Hospital. We are grateful to the members of the National Institutes of Health in Harare and the Biochemistry Department at University of Zimbabwe for technical and logistical support. This research received financial support from the National Health and Medical Research Council of Australia (NHMRC) (Program Grant no: APP1037304), the Wellcome Trust UK (Grant no: WT082028MA), the Cunningham Trust, the Carnegie Trust for the Universities of Scotland, and the Shanghai Science and Technology Commission (Grant no: 15ZR1444300). DM is an NHMRC Senior Principal Research Fellow, AL and DD are NHMRC Principal Research Fellows. NY is an NHMRC Early Career Research Fellow.

References


43. Moloney NA, Webbe G. Antibody is responsible for the passive transfer of immunity to mice from rabbits, rats or mice vaccinated with attenuated Schisto- soma japonicum cercariae. Parasitology (1999) 100(Pt 2):235–9. doi: 10.1017/ S0031229X00061230


**Immunologic profiling of schistosomiasis infection**

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 Pearson, Becker, Driguez, Young, Gaze, Mendes, Li, Doolan, Midzi, Mduluza, McManus, Wilson, Bethony, Nausch, Mutapi, Felgner and Loukas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.